Performance · Recovery · Longevity

Shopping Cart (0)

Catalogue

Shop

Browse “Muscle/Performamnce, Recovery/Tissue, Weight Loss/Metabolic and Research Peptides“ and advanced wellness compounds. Prices are shown in South African Rand (ZAR).

Research peptides & wellness compounds

Select a product to view available quantities, specifications and regulatory status. Quantities, documentation and pricing are confirmed before dispatch.

TB-500 (UPA Platinum).0

Category:
Recovery / Tissue
SKU:
TRW-TB500
Price:
R 680.00
{{variant.name}}:
{{opt.name}}
{{opt.value ? '' : opt.name}}
{{opt.value ? '' : opt.name}}
Description

TEST RUN WELLNESS TB-500 5 | 5 mg Advanced Tissue Repair Peptide (Self-Mix Vial)

 

TB-500 5 mg – Synthetic fragment of the naturally occurring actin-binding protein thymosin beta-4. Mobilises repair cells to the site of injury, builds new blood supply into damaged tissue, and accelerates recovery across muscle, tendon, ligament and skin. Includes 2 ml bacteriostatic water.

 

Product Overview

TB-500 is a synthetic version of thymosin beta-4, one of the most abundant and most studied actin-binding proteins in the human body. Thymosin beta-4 is present in virtually every cell and tissue type, with its highest concentrations in platelets, white blood cells and wound fluid — the exact locations from which tissue repair is orchestrated. It is released in large quantities at the site of injury, which is the clearest indication of its physiological role.

 

The TB-500 fragment carries the active region of the parent protein: the sequence Ac-Ser-Asp-Lys-Pro, a short tetrapeptide known as Ac-SDKP, together with the actin-binding domain. That fragment is what confers the compound's defining pharmacological property — the ability to bind and sequester G-actin, the monomeric building block of the cellular skeleton. By regulating actin availability, TB-500 governs cell shape, motility and migration, and it is that control over cell movement which allows repair cells to travel to where they are needed.

 

The compound has an unusually broad and well-documented research record, spanning muscle, tendon, ligament, skin, corneal and cardiac tissue. It is also one of the few peptides with a long-established history of veterinary use, particularly in performance horses, where it is used for tendon and ligament injuries — an application that reflects the depth of its soft-tissue repair research rather than a lack of scientific interest in it.

 

TB-500 is supplied here as a 5 mg lyophilised powder in a self-mix vial with 2 ml bacteriostatic water. Reconstituting the full 2 ml yields 2 500 mcg/ml.

 

How TB-500 Works: Actin Sequestration and Cell Migration Pathway

TB-500's mechanism sits upstream of everything else in the healing cascade. It does not deliver a repair signal to tissue; it enables the cells that perform repair to get there in the first place.

 

The peptide binds G-actin, the monomeric form of the cytoskeletal protein actin, and sequesters it. Actin polymerisation and depolymerisation is the engine of cell motility — a cell extends its leading edge by polymerising actin and retracts its trailing edge by depolymerising it. By regulating the availability of G-actin, TB-500 directly controls the rate at which cells can move. This is the mechanism behind its most consistently reported effect: the enhanced migration of endothelial cells, keratinocytes, fibroblasts and inflammatory cells toward a site of injury.

 

The second arm of the mechanism is angiogenesis. TB-500 stimulates the migration and differentiation of endothelial cells into new capillary structures, improving blood supply to damaged, poorly perfused tissue. Because tendon and ligament injuries heal slowly precisely because of their limited vascularity, restoring blood flow to those structures is a prerequisite for repair — and it is why TB-500's effects are most pronounced in exactly the tissue types that otherwise recover poorly.

 

The third arm is cell survival and anti-inflammatory activity. TB-500 has been reported to protect cells from apoptosis under stress, to reduce inflammatory cell infiltration and pro-inflammatory cytokine expression, and to support the deposition and organisation of collagen in healing tissue. It also upregulates the enzymes involved in matrix remodelling, supporting the transition from provisional repair tissue to organised, load-bearing tissue.

 

The fourth arm concerns the Ac-SDKP fragment specifically. Ac-SDKP is a naturally occurring tetrapeptide with documented anti-fibrotic activity: it reduces the deposition of excess collagen characteristic of fibrosis and scar formation. This makes TB-500's remodelling profile unusually balanced — it promotes collagen organisation where tissue needs rebuilding while limiting the excessive, disorganised collagen deposition that produces scar tissue and adhesions.

 

Body Recomposition Benefits

TB-500's benefits are reparative. It improves the speed and quality of recovery from injury and training-induced tissue damage; it is not a muscle-building agent and has no activity at the androgen receptor.

 

In research models, TB-500 has been used to study recovery across the tissue types that most commonly limit training continuity. In muscle, it has been reported to accelerate the restoration of contractile function after induced injury, with reduced fibrosis and improved regeneration of muscle fibres. In tendon and ligament, its most characteristic application, it is reported to promote the migration of repair cells into the injury site, restore vascular supply, and improve the organisation and tensile quality of the repaired tissue — the basis of its long-standing veterinary use for tendon injuries in performance animals.

 

In skin and dermal tissue, TB-500 has been studied for accelerated wound closure, improved scar appearance and reduced adhesion formation. In corneal tissue, thymosin beta-4 is one of the better-characterised repair peptides in the literature, with reported acceleration of epithelial healing. Cardiac research on the parent protein describes reduced scar formation and improved functional recovery after injury, an area of substantial ongoing scientific interest.

 

The anti-fibrotic contribution of the Ac-SDKP fragment is relevant to how well repaired tissue ultimately performs. Tissue that heals with excessive scar collagen is weaker, less flexible and more prone to re-injury than tissue that heals with organised collagen — so limiting fibrosis is not a cosmetic effect but a functional one.

 

Applied to training, the intended benefit is a shortened time-to-return after strain, tendon irritation or ligament injury, and better quality of the healed tissue once return is achieved. This is a recovery-continuity benefit rather than a direct performance benefit: the value is in the training sessions and weeks that are not lost to injury.

 

It should be noted that TB-500 is not a muscle-building compound, does not increase protein synthesis directly, and is not a fat-loss agent. Its reported benefits concern the repair and remodelling of existing tissue, and its role in a body recomposition protocol is to protect the training continuity on which every other intervention depends.

 

Titration Protocol

TB-500 is administered via subcutaneous injection. The protocol is titrated by injury status rather than by body weight, progressing from general recovery maintenance to loading doses for significant injury.

A standard titration schedule is as follows:

 

· General Recovery: 2.0 – 2.5 mg, once or twice weekly — maintenance and preventative recovery support

 

· Moderate Injury: 2.5 – 5.0 mg, twice weekly — tendon, ligament and muscle repair

 

· Chronic Injury: 5.0 mg, twice weekly for 2–4 weeks — loading phase for deep tissue and long-standing injury

Volume figures assume reconstitution of the full 5 mg vial with the included 2 ml bacteriostatic water, giving 2 500 mcg/ml. At that concentration, 2.5 mg is 1.0 ml and 5 mg is 2.0 ml; 1 mg is 0.40 ml and 2 mg is 0.80 ml for finer adjustment.

 

The conventional structure separates a loading phase from a maintenance phase. A loading phase — typically 5 mg twice weekly for 2–4 weeks in the moderate and chronic tiers — is used to achieve a therapeutic effect in tissue that is actively repairing. This is followed by a maintenance phase at 2.0–2.5 mg once or twice weekly, continued for the remainder of the cycle. Reported cycles run 4–6 weeks for a defined injury and up to 8–12 weeks for chronic or multi-site recovery, followed by a break before repeat cycling.

 

Subcutaneous administration into abdominal or thigh fat is standard. For localised injury, injection into the subcutaneous tissue as close to the affected structure as is anatomically reasonable is the conventional approach; abdominal injection is used for systemic recovery protocols. Rotate sites between abdomen, thigh and upper arm, and do not inject into an acutely inflamed, infected or recently operated area.

 

Reconstitute by directing the diluent down the inside wall of the vial and swirling gently — do not shake, to avoid denaturing the peptide. Use a new insulin or 0.5-inch needle per injection and disinfect the vial septum and injection site with an alcohol swab. Inject at a 45–90° angle into pinched subcutaneous tissue.

Store the lyophilised vial in a cool, dark place at 2–8 °C. Store the reconstituted solution refrigerated at 2–8 °C, protected from light, and do not freeze it after reconstitution.

 

Dose escalation should only proceed if the current dose is well tolerated. TB-500's reported effects accumulate over weeks rather than appearing acutely, so a loading phase should be completed before concluding that a dose level is insufficient. Do not stack two loading phases back to back; follow the cycle with a washout period before repeating.

 

Combination Therapy

TB-500 is most often used in combination, particularly with other repair-orientated peptides. This is where the compound's practical value is highest.

 

· TB-500 + BPC-157: The most widely used repair pairing, sometimes termed the "Wolverine stack." BPC-157 acts primarily on angiogenesis and local vascular supply at the injury site, while TB-500 drives cell migration and actin-mediated repair across a broader tissue field. The mechanisms are complementary rather than overlapping, and the combination is the most commonly reported protocol for tendon, ligament and muscle injury in non-competing lifters.

 

· TB-500 + GHK-Cu: Extends the repair focus into dermal collagen and connective tissue remodelling. GHK-Cu supplies the copper-dependent collagen cross-linking and gene-modulation signal while TB-500 contributes cell migration and anti-fibrotic activity, making the pairing well suited to skin quality and post-procedure recovery alongside deeper soft-tissue work.

 

· TB-500 + GH secretagogues (CJC-1295 with or without DAC, ipamorelin): The rationale is that elevated pulsatile GH and IGF-1 raise systemic collagen synthesis and provide anabolic substrate while TB-500 mobilises repair cells and restores vascular supply to the injured structure. This is a mechanistic argument, and combined use increases total injection burden.

 

· TB-500 + MOTS-c: Directed at the metabolic side of recovery — mitochondrial efficiency and fat oxidation — alongside structural tissue repair. Popular in protocols targeting body recomposition with concurrent injury recovery.

 

· TB-500 + graded rehabilitation: The most defensible combination is pharmacological support alongside progressive loading and physiotherapy. Repaired tissue requires mechanical stimulus to organise along lines of stress, and without graded loading the remodelling benefit is not fully realised. No peptide substitutes for progressive load.

 

· Compounds that should not be assumed compatible: No interaction studies exist between TB-500 and anticoagulants, antiplatelets, NSAIDs, corticosteroids or immunosuppressants. Thymosin beta-4 has documented roles in vascular and cardiac tissue, and concurrent anticoagulant or antiplatelet therapy warrants explicit clinical review before use. Corticosteroid injection at the same anatomical site conflicts with the compound's intent and is generally discouraged concurrently.

 

All combination approaches should be pursued under professional medical supervision.

 

Clinical Trial Record

Thymosin beta-4, the parent protein from which TB-500 is derived, is one of the most extensively characterised repair molecules in the research literature — a record that spans more than four decades and multiple tissue systems, and which forms the scientific foundation for the TB-500 fragment.

 

The mechanism work is comprehensive and consistent. Thymosin beta-4 was identified as the principal G-actin sequestering peptide in mammalian cells, establishing the actin-regulation mechanism that governs cell motility. Its release from platelets and white blood cells at wound sites, its upregulation in healing tissue, and its angiogenic, anti-apoptotic and anti-inflammatory activities have all been documented across independent research groups. The Ac-SDKP fragment's anti-fibrotic activity has its own substantial body of research, including work on cardiac and renal fibrosis.

 

In tissue-specific research, thymosin beta-4 and TB-500 have been studied for dermal wound healing with reported acceleration of wound closure and improved scar outcomes; for corneal epithelial repair, one of the better-characterised applications; for cardiac tissue, where the parent protein has been reported to promote cell survival and reduce scar formation after injury; and for tendon, ligament and muscle repair, including the actin-mediated mobilisation of repair cells into injury sites. The depth of this record is the reason the compound has held a permanent place in soft-tissue repair research.

 

TB-500's most established practical record is in veterinary medicine, where it has been used for years in the treatment of tendon and ligament injuries in performance horses. That application is directly relevant: equine superficial digital flexor tendon injury is one of the closest naturally occurring analogues to human tendinopathy, and the compound's sustained use in that setting reflects consistent clinical reporting of benefit in tendon repair.

 

In human application, the picture is different and should be stated plainly. TB-500 itself has not been the subject of large randomised controlled human trials, and its reported human benefits derive from the substantial mechanistic, preclinical and veterinary record rather than from controlled human outcome data.

 

The parent protein thymosin beta-4 has been investigated in human clinical settings — including ophthalmic and cardiac research — which provides supportive context for the fragment's mechanism, but those studies concern the parent molecule and different indications.

 

The compound's human record is best understood as a well-characterised mechanism with a strong preclinical and veterinary foundation, applied in practice ahead of formal human trial confirmation.

 

Technical Specifications

· Product Name: TB-500 5
· Peptide: TB-500 (thymosin beta-4 fragment; actin-binding peptide, Ac-SDKP sequence)
· Concentration: 5mg per vial
· Form: Self-mix vial — lyophilised powder
· Reconstitution: Requires bacteriostatic water for reconstitution (2ml included)
· Reconstituted concentration: 2 500 mcg/ml (5mg in 2ml)
· Administration: Subcutaneous injection, once or twice weekly
· Cycle length: 4–6 weeks for defined injury; 8–12 weeks for chronic recovery, with a break before repeat cycling
· Loading phase: 5mg twice weekly for 2–4 weeks in moderate to chronic tiers
· Maintenance phase: 2.0–2.5mg once or twice weekly
· Storage: 2–8 °C, protected from light; do not freeze after reconstitution
· Supplier: Test Run Wellness (Wellness.testrun)

 

⚕️ Important Medical Notice

Please consult your medical practitioner regarding your body requirements, as the dosing information provided contains guideline dosages. TB-500 is intended for use under professional medical supervision.

 

Do not use in pregnancy or breastfeeding, or in anyone under 18 years of age. Do not use with active malignancy or a history of malignancy. Use with caution — and only under clinician supervision — in patients with cardiovascular disease, active bleeding, coagulopathy, or those on anticoagulant or antiplatelet therapy.

Regulatory notice. Test Run Wellness is an independent supplier and is not the manufacturer of the products referenced. No product should be used without appropriate regulatory authorisation and professional medical oversight.